BridgeBio Pharma

@BridgeBioPharma

We move at the speed of patient need. We exist to bring meaningful medicines to people living with genetic conditions. $BBIO

Palo Alto, California

Joined January 2021

BridgeBio Pharma
@BridgeBioPharma
8h
We are thrilled to share two oral presentations and three posters on new ATTR-CM data at the @escardio Congress 2026. As part of BridgeBio's partnership with Yale's @cards_lab advance AI networks for earlier detection of ATTR-CM, three additional posters also will be presented.
BridgeBio Pharma
@BridgeBioPharma
Aug 21
We're proud to announce our nomination for #PrixGalien's Best Product for Orphan Drug/Rare Diseases. This recognition reflects our commitment to addressing the unmet need for patients with ATTR-CM, a life-threatening progressive heart condition, and our broader mission to design
BridgeBio Pharma
@BridgeBioPharma
Aug 20
Join us on the 1st day of #ESC26 to hear experts discuss how timely detection matters in #ATTR-CM, emerging AI screening approaches and the clinical outcomes observed with early therapy initiation. Friday, Aug 28 | 10:00 AM CEST.
BridgeBio Pharma
@BridgeBioPharma
Aug 18
New episode of #OnRarePodcast: Pete Schmidt, MD, MSc., Chief Medical Officer of GondolaBio, joins Ashley, who lives with EPP, to explain the science behind EPP and XLP, from severe photosensitivity to the risk of liver damage. Listen: bit.ly/4yWorTK #OnRare #EPP
00:00
BridgeBio Pharma
@BridgeBioPharma
Aug 10
We reported our Q2 2026 financial results today. Full results here to take a look at what’s ahead: bit.ly/4bAKnKb